MoonLake Immunotherapeutics (MLTX)
11.07
+0.04
(+0.36%)
USD |
NASDAQ |
Nov 20, 16:00
11.07
0.00 (0.00%)
After-Hours: 20:00
MoonLake Immunotherapeutics Shareholders Equity (Quarterly) : 381.63M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 381.63M |
| June 30, 2026 | 428.20M |
| March 31, 2026 | 254.02M |
| December 31, 2025 | 304.48M |
| September 30, 2025 | 288.91M |
| June 30, 2025 | 353.73M |
| March 31, 2025 | 407.52M |
| December 31, 2024 | 446.82M |
| September 30, 2024 | 488.20M |
| June 30, 2024 | 520.66M |
| March 31, 2024 | 542.55M |
| December 31, 2023 | 495.68M |
| September 30, 2023 | 424.93M |
| Date | Value |
|---|---|
| June 30, 2023 | 489.80M |
| March 31, 2023 | 42.00M |
| December 31, 2022 | 48.90M |
| September 30, 2022 | 55.29M |
| June 30, 2022 | 63.51M |
| March 31, 2022 | 24.40M |
| December 31, 2021 | -11.64M |
| September 30, 2021 | 110.16M |
| June 30, 2021 | 112.26M |
| March 31, 2021 | 112.41M |
| December 31, 2020 | 112.48M |
| September 30, 2020 | 0.02M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 5.820B |
| AC Immune SA | 32.27M |
| CRISPR Therapeutics AG | 1.648B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 540.72M |
| Total Liabilities (Quarterly) | 159.09M |
| Debt to Equity Ratio | 0.2663 |
| Current Ratio | 9.128 |
| Net Debt Paydown Yield | -0.52% |